Back to Quality Research
BSXBoston Scientific Corp
Health Care · Health Care Equipment · Large
$45.69−0.70%
As of 23 Oct 2026Mkt cap $70.1B
Stage 13
AVOID
Fundamentals
60.6/75
Technical
5.0/15
Independent
65.6/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- +2.3%
- 3M
- +0.4%
- 6M
- −26.4%
- 1Y
- −56.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 18.5xHist median 61.9x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 9.6%
- Operating margin
- 16.5%
- FCF margin
- 18.2%
- Current ratio
- 1.6x
Growth
- Revenue growth
- +19.9%Latest FY YoY
- Revenue CAGR
- +14.0%
- EPS CAGR
- +29.5%
- FCF CAGR
- +29.1%
Capital
- Share-count trend
- +1.1%3Y annualised
- Net debt
- $9.2B2.0x OCF
Annual trend
- CAGR 2021–2025
- +14.0%
- Latest · 2025
- $20B
- YoY
- +19.9%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- UNRESEARCHED · NEW RESEARCH
Key takeaway
Awaiting four-lens research.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-28
- New current Route A/Route B candidate has no completed four-lens research.
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded